Cancer vaccines have long held promise as a potential cancer treatment. Now, a new vaccine platform has been successfully engineered by Defence Breakthrough that may finally make cancer vaccines a reality. The Accum-mRNA Vaccine represents a significant step forward in cancer treatment, and it has already begun its in vivo clinical trial, giving hope to millions of patients worldwide. In this article, we will explore the breakthrough technology behind the Accum-mRNA Vaccine and the impact it could have on cancer therapy.
Defence Therapeutics Inc., a Canadian biopharmaceutical company specializing in the development of immune-oncology vaccines and drug delivery technologies, has successfully established a strategy that conjugates mRNA (messenger ribonucleic acid) molecules to Accum™. The company’s final product is stable, and an SOP has been finalized to apply the same method to any chosen mRNA molecule.
The field of mRNA vaccination holds great promise over the use of other vaccination modalities. However, mRNA delivered to target cells makes them prone to harsh intracellular conditions such as the exhaustive acidity and enzymatic reactions found within endosomal lumens. As such, captured mRNA molecules may be destroyed before even reaching the cytoplasm where they are normally translated into proteins or long polypeptide chains.
Despite representing a promising technology, mRNA vaccines have not reached their full potential yet. By conjugating mRNA to Accum™, the immunogenicity of the vaccine is expected to be enhanced, resulting in a powerful immune response, says Dr. Rafei, the VP Research and Development of Defence Therapeutics.
The company anticipates that the potency of the Accum™-mRNA vaccine will be tested in animals on cancer solid T-cell lymphoma first, then subsequently on additional cancer solid tumors. Defence plans to develop its own Accum™-linked mRNA vaccines for different cancer indications. In parallel, the company is actively working on establishing partnerships with companies currently testing/developing mRNA vaccines for both immune-oncology and infectious disease indications.
According to Precedence Research, the mRNA therapeutics market size is projected to surpass around USD 128.14 billion by 2030 and growing at a registered CAGR of 13.03% from 2022 to 2030.
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC (antibody-drug conjugate) products using its proprietary platform. The core of Defence Therapeutics’ platform is the ACCUM™ technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illnesses such as cancer and infectious diseases.
Investors are cautioned that any forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected in the forward-looking statements. Neither the CSE nor its market regulator accepts responsibility for the adequacy or accuracy of this release.
In conclusion, Defence Therapeutics continues to provide innovative solutions for vaccine development and delivery in the biopharmaceutical industry. By using the company’s ACCUM™ technology, enhanced efficacy and potency can be achieved, indicating great promise in the future of mRNA vaccinations.
In conclusion, the development of the in vivo Accum-mRNA Cancer Vaccine is a significant breakthrough in cancer research. This innovative vaccine platform not only stimulates the immune system to target and destroy cancer cells but also has the potential to be customized for any type of cancer. With this breakthrough, we are at the forefront of a new era in cancer treatment that promises hope for many who are suffering from this devastating disease. We look forward to seeing the results of the in vivo Accum-mRNA Cancer Vaccine Program, and we remain optimistic about the future of cancer immunotherapy.
